Mark W. Kieran

Active 1987–2025

138
Papers
25,942
Citations
93
h-index
133
i10-index

Citations

Citations per year for Mark W. Kieran1984: 4 citations1987: 5 citations1988: 13 citations1989: 15 citations1990: 34 citations1991: 91 citations1992: 107 citations1993: 99 citations1994: 45 citations1995: 54 citations1996: 41 citations1997: 45 citations1998: 37 citations1999: 42 citations2000: 39 citations2001: 28 citations2002: 45 citations2003: 41 citations2004: 64 citations2005: 107 citations2006: 115 citations2007: 131 citations2008: 133 citations2009: 141 citations2010: 168 citations2011: 161 citations2012: 153 citations2013: 201 citations2014: 252 citations2015: 286 citations2016: 264 citations2017: 257 citations2018: 264 citations2019: 990 citations2020: 1,115 citations2021: 1,049 citations2022: 881 citations2023: 653 citations2024: 850 citations2025: 369 citations2026: 4 citations1985–1986: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,917 citing papers, 31.8% of this breakdownChina: 1,006 citing papers, 8.1% of this breakdownGermany: 901 citing papers, 7.3% of this breakdownUnited Kingdom: 749 citing papers, 6.1% of this breakdownCanada: 565 citing papers, 4.6% of this breakdownFrance: 554 citing papers, 4.5% of this breakdownItaly: 487 citing papers, 3.9% of this breakdownNetherlands: 355 citing papers, 2.9% of this breakdownAustralia: 309 citing papers, 2.5% of this breakdownSpain: 297 citing papers, 2.4% of this breakdownJapan: 292 citing papers, 2.4% of this breakdownSwitzerland: 258 citing papers, 2.1% of this breakdown
0%31.8%Other 21.4%

Fields

  • Medicine46.9%
  • Biochemistry, Genetics and Molecular Biology41.6%
  • Immunology and Microbiology4.5%
  • Neuroscience1.6%
  • Engineering1.3%
  • Materials Science1.1%
  • Other3%

Topics

  • Glioma Diagnosis and Treatment8%
  • Neuroblastoma Research and Treatments2.3%
  • Epigenetics and DNA Methylation2%
  • Cancer Cells and Metastasis2%
  • Neurofibromatosis and Schwannoma Cases1.8%
  • Immune cells in cancer1.8%
  • Other82.1%

Coauthors

All papers

Open in search
  1. Challenges to curing primary brain tumours

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Reviews Clinical Oncology 2019 cited by 972

  2. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Amedeo A. Azizi, Tracy T. Batchelor, Matthew P. Frosch, Maria Martinez‐Lage, Mark W. Kieran, Pratiti Bandopadhayay, Rameen Beroukhim, G. Fritsch, Gad Getz, Orit Rozenblatt–Rosen, Kai W. Wucherpfennig, David N. Louis, Michelle Monje, Irene Slavc, Keith L. Ligon, Todd R. Golub, Aviv Regev, B Bernstein, Mario L. Suvà - Science 2018 cited by 756

  3. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Klaus Charissé, Mark W. Kieran, Kevin Fitzgerald, Matthias Nahrendorf, Dganit Danino, Rubin M. Tuder, Ulrich H. von Andrian, Akin Akinc, Dipak Panigrahy, Avi Schroeder, Victor Koteliansky, Róbert Langer, Daniel G. Anderson - Nature Nanotechnology 2014 cited by 573

  4. Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hetal Dholaria, Renee Doughman, Martin Benesch, Rachid Drissi, Javad Nazarian, Nada Jabado, Nathalie Boddaert, Pascale Varlet, G Giraud, David Castel, Stéphanie Puget, Chris Jones, Esther Hulleman, Piergiorgio Modena, Marzia Giagnacovo, Manila Antonelli, Torsten Pietsch, Gerrit H. Gielen, David Jones, Dominik Sturm, Stefan M. Pfister, Nicolas U. Gerber, Michael A. Grotzer, Elke Pfaff, André O. von Bueren, Darren Hargrave, Guirish A. Solanki, Filip Jadrijević Cvrlje, Gertjan J.L. Kaspers, W. Peter Vandertop, Jacques Grill, Simon Bailey, Veronica Biassoni, Maura Massimino, Raphaël Calmon, Esther Sánchez, Brigitte Bison, Monika Warmuth‐Metz, James Leach, Blaise V. Jones, Dannis G. van Vuurden, Christof M. Kramm, Maryam Fouladi - Journal of Clinical Oncology 2018 cited by 435

  5. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Maria Luisa Garrè, Paolo Nozza, Samantha Mascelli, Alessandro Raso, Sabine Mueller, Theodore Nicolaides, Karen Silva, Romain Perbet, Alexandre Vasiljevic, Cécile Faure‐Conter, Didier Frappaz, Sarah Leary, Courtney A. Crane, Aden Ka‐Yin Chan, Ho‐Keung Ng, Zhifeng Shi, Ying Mao, Elizabeth Finch, David D. Eisenstat, Bev Wilson, Anne Sophie Carret, Péter Hauser, David Sumerauer, Lenka Krsková, Valérie Larouche, Adam Fleming, Shayna Zelcer, Nada Jabado, James T. Rutka, Peter B. Dirks, Michael D. Taylor, Shiyi Chen, Ute Bartels, Annie Huang, David W. Ellison, Éric Bouffet, Cynthia Hawkins, Uri Tabori - Journal of Clinical Oncology 2017 cited by 346

  6. Identification of fibroblast heterogeneity in the tumor microenvironment

    Authors: , , , - Cancer Biology & Therapy 2006 cited by 677

  7. Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation–Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study

    Authors: , , , , , , , , , , , , , , - Clinical Cancer Research 2019 cited by 212

  8. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ursula Weber, Marc Zapatka, Benjamin Raeder, Matthias Schlesner, Catherine L. Worth, Cynthia C. Bartholomae, Christof von Kalle, Charles D. Imbusch, Sylwester Radomski, Chris Lawerenz, Peter van Sluis, Jan Köster, Richard Volckmann, Rogier Versteeg, Hans Lehrach, Camelia Monoranu, Beate Winkler, Andreas Unterberg, Christel Herold‐Mende, Till Milde, Andreas E. Kulozik, Martin Ebinger, Martin U. Schuhmann, Yoon‐Jae Cho, Scott L. Pomeroy, Andreas von Deimling, Olaf Witt, Michael D. Taylor, Stephan Wolf, Matthias A. Karajannis, Charles G. Eberhart, Wolfram Scheurlen, Martin Hasselblatt, Keith L. Ligon, Mark W. Kieran, Jan O. Korbel, Marie‐Laure Yaspo, Benedikt Brors, Jörg Felsberg, Guido Reifenberger, V. Peter Collins, Nada Jabado, Roland Eils, Peter Lichter - Nature Genetics 2013 cited by 835

  9. Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rainer König, Rameen Beroukhim, Guillaume Bergthold, Peter van Sluis, Richard Volckmann, Jan Köster, Rogier Versteeg, Sabine Schmidt, Stephan Wolf, Chris Lawerenz, Cynthia C. Bartholomae, Christof von Kalle, Andreas Unterberg, Christel Herold‐Mende, Silvia Höfer, Andreas E. Kulozik, Andreas von Deimling, Wolfram Scheurlen, Jörg Felsberg, Guido Reifenberger, Martin Hasselblatt, John R. Crawford, Gerald A. Grant, Nada Jabado, Arie Perry, Cynthia Cowdrey, Sydney Croul, Gelareh Zadeh, Jan O. Korbel, François Doz, Olivier Delattre, Gary D. Bader, Martin G. McCabe, V. Peter Collins, Mark W. Kieran, Yoon‐Jae Cho, Scott L. Pomeroy, Olaf Witt, Benedikt Brors, Michael D. Taylor, Ulrich Schüller, Andrey Korshunov, Roland Eils, Robert J. Wechsler‐Reya, Peter Lichter, Stefan M. Pfister - Cancer Cell 2014 cited by 779

  10. Pediatric high-grade glioma: biologically and clinically in need of new thinking

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Neuro-Oncology 2016 cited by 364

  11. Long‐term outcome of 4,040 children diagnosed with pediatric low‐grade gliomas: An analysis of the Surveillance Epidemiology and End Results (SEER) database

    Authors: , , , , , , , , , , , , - Pediatric Blood & Cancer 2014 cited by 320

  12. Resolvins suppress tumor growth and enhance cancer therapy

    Authors: , , , , , , , , , , , , , , , , , , , , - The Journal of Experimental Medicine 2017 cited by 257

  13. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anne‐Sophie Carret, Benjamin Ellezam, Louis Crevier, Álmos Klekner, László Bognár, Péter Hauser, Miklós Garami, John S. Myseros, Zhifeng Dong, Peter M. Siegel, Hayley Malkin, Azra H. Ligon, Steffen Albrecht, Stefan M. Pfister, Keith L. Ligon, Jacek Majewski, Nada Jabado, Mark W. Kieran - Nature Genetics 2014 cited by 467

  14. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Paul Van Hummelen, Mariarita Santi, Anna Maria Buccoliero, Mirko Scagnet, Daniel C. Bowers, Caterina Giannini, Stéphanie Puget, Cynthia Hawkins, Uri Tabori, Álmos Klekner, László Bognár, Peter C. Burger, Charles G. Eberhart, Fausto J. Rodríguez, D. Ashley Hill, Sabine Mueller, Daphne A. Haas‐Kogan, Joanna J. Phillips, Sandro Santagata, Charles D. Stiles, James E. Bradner, Nada Jabado, Alon Goren, Jacques Grill, Azra H. Ligon, Liliana Goumnerova, Angela J. Waanders, Phillip B. Storm, Mark W. Kieran, Keith L. Ligon, Rameen Beroukhim, Adam Resnick - Nature Genetics 2016 cited by 281

  15. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Adam Resnick, Mark W. Kieran, Gad Getz, Sandro Santagata - Nature Genetics 2014 cited by 512

  16. Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome

    Authors: , , , , , , , - Circulation 2014 cited by 238

  17. Role of Collagen Matrix in Tumor Angiogenesis and Glioblastoma Multiforme Progression

    Authors: , , , , , - American Journal Of Pathology 2013 cited by 192

  18. Clinical and treatment factors determining long‐term outcomes for adult survivors of childhood low‐grade glioma: A population‐based study

    Authors: , , , , , , , , , , , , , , , , , , , - Cancer 2016 cited by 185

  19. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome

    Authors: , , , , , , , - JAMA 2018 cited by 220

  20. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson–Gilford progeria syndrome

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2012 cited by 370

  21. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Darryl C. Zeldin - Journal of Clinical Investigation 2011 cited by 291

  22. Pediatric low-grade gliomas: next biologically driven steps

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Neuro-Oncology 2017 cited by 165

  23. Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2019 cited by 137

  24. BET Bromodomain Inhibition of MYC -Amplified Medulloblastoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2013 cited by 351